SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization may be delayed.**

Drug Requested: Cosentyx® SQ (secukinumab) **(Pharmacy)**

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ **Date of Birth:** _____

Prescriber Name: _____

Prescriber Signature: _____ **Date:** _____

Office Contact Name: _____

Phone Number: _____ **Fax Number:** _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code:** _____

Weight (if applicable): _____ **Date weight obtained:** _____

Recommended Dosing: (select **ONE** of the following)

- ❑ Prescribed with a loading dose
- ❑ Prescribed without a loading dose

NOTE: The Health Plan considers the use of concomitant therapy with more than one biologic immunomodulator (e.g., Dupixent, Entyvio, Humira, Rinvoq, Stelara) prescribed for the same or different indications to be experimental and investigational. Safety and efficacy of these combinations has **NOT** been established and will **NOT** be permitted.

- Will the member be discontinuing a previously prescribed biologic if approved for requested medication?

  ❑ Yes **OR** ❑ No

- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

  Medication to be discontinued: _____ **Effective date:** _____

  Medication to be initiated: _____ **Effective date:** _____

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. **Check the diagnosis below that applies.**

❑ Diagnosis: Active Ankylosing Spondylitis

Dosing:

- ❑ Adults:
  - ❑ **With a loading dose:** 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
  - ❑ **Without a loading dose:** 150 mg every 4 weeks
- ❑ Pediatric 12 years and older: Recommended dosage based on body weight and administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter

Body Weight at Time of Dosing	Recommended Dose
< 50 kg	75 mg
≥ 50 kg	150 mg

- ❑ Member is ≥ 12 years of age and has a diagnosis of active **ankylosing spondylitis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member tried and failed, has a contraindication, or intolerance to **ONE** NSAID
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product	❑ Enbrel®	❑ Rinvoq®
❑ Taltz®	❑ generic tofacitinib/ER	

  - ❑ Member has been established on Cosentyx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cosentyx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Non-Radiographic Axial Spondyloarthritis

Dosing:

- ❑ **With a loading dose:** 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
- ❑ **Without a loading dose:** 150 mg every 4 weeks

- ❑ Member has a diagnosis of active **non-radiographic axial spondyloarthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist**
- ❑ Member has at least **ONE** of the following objective signs of inflammation:
  - ❑ C-reactive protein [CRP] levels above the upper limit of normal
  - ❑ Sacroiliitis on magnetic resonance imaging [MRI] (indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints)

(Continued on next page)

- ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** NSAIDs
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the following **(verified by chart notes or pharmacy paid claims)**:

❑ Cimzia®	❑ Rinvoq®	❑ Taltz®

  - ❑ Member has been established on Cosentyx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cosentyx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Active Psoriatic Arthritis or Active Enthesitis-related Arthritis

Dosing:

- ❑ Adults:
  - ❑ **With a loading dose:** 150 mg at weeks 0, 1, 2, 3, and 4 followed by 150 mg every 4 weeks
  - ❑ **Without a loading dose:** 150 mg every 4 weeks
- ❑ Pediatric members 2 (PsA) to 4 (ERA) years and older: Recommended dosage based on body weight and administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter

Body Weight at Time of Dosing	Recommended Dose
≥ 15 kg and < 50 kg	75 mg
≥ 50 kg	150 mg

- ❑ Member must meet **ONE** of the following age and diagnosis requirements:
  - ❑ Member is ≥ 2 years of age with a diagnosis of active **psoriatic arthritis**
  - ❑ Member is ≥ 4 years of age with a diagnosis of active **enthesitis-related arthritis**
- ❑ Prescribed by or in consultation with a **Rheumatologist or Dermatologist**
- ❑ Member meets **ONE** of the following:
  - ❑ Member has tried and failed at least **ONE** of the following **DMARD** therapies for at least **three (3) months**:
    - ❑ cyclosporine
    - ❑ leflunomide
    - ❑ methotrexate
    - ❑ sulfasalazine
  - ❑ Member has previously tried and failed another biologic medication other than the requested medication (e.g., adalimumab, Otezla, Skyrizi)

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product	❑ Enbrel®	❑ Otezla®/Otezla XR™
❑ Rinvoq®/ Rinvoq® LQ	❑ Skyrizi®	❑ Taltz®
❑ generic tofacitinib/ER/solution	❑ Tremfya®	❑ Preferred ustekinumab product

  - ❑ Member has been established on Cosentyx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cosentyx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ Diagnosis: Moderate-to-Severe Plaque Psoriasis

Dosing:

- ❑ Adults: 300 mg once weekly at weeks 0, 1, 2, 3, and 4 followed by 300 mg every 4 weeks
- ❑ Pediatric members 6 years and older: Recommended dosage based on body weight and administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter

Body Weight at Time of Dosing	Recommended Dose
< 50 kg	75 mg
≥ 50 kg	150 mg

- ❑ Member is ≥ 6 years of age and has a diagnosis of **moderate-to-severe plaque psoriasis**
- ❑ Prescribed by or in consultation with a **Dermatologist**
- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed at least **ONE** of either Phototherapy or Alternative Systemic Therapy for at least **three (3) months**, unless member has a contraindication or intolerance to both phototherapy and alternative systemic therapies **(check each tried below)**:

❑ **Phototherapy:** ❑ **UV Light Therapy** ❑ NB UV-B ❑ PUVA	❑ **Alternative Systemic Therapy:** ❑ **Oral Medications** ❑ acitretin ❑ methotrexate ❑ cyclosporine

  - ❑ Member has tried and failed another biologic medication other than the requested medication (e.g., adalimumab, Otezla, ustekinumab)

(Continued on next page)

- ❑ Member meets **ONE** of the following:
  - ❑ Member tried and failed, has a contraindication, or intolerance to **TWO** of the **PREFERRED** biologics below **(verified by chart notes or pharmacy paid claims)**:

❑ Preferred adalimumab product	❑ Enbrel®	❑ Otezla®/Otezla XR™	❑ Skyrizi®
❑ Sotyktu™	❑ Taltz®	❑ Tremfya®	❑ Preferred ustekinumab product

  - ❑ Member has been established on Cosentyx® for at least 90 days **AND** prescription claims history indicates **at least a 90-day supply of Cosentyx was dispensed within the past 130 days (verified by chart notes or pharmacy paid claims)**

❑ **Diagnosis: Moderate-to-Severe Hidradenitis Suppurativa (HS)**
Dosing: SubQ:
- ❑ Adults:
  - ❑ **Initial**: 300 mg administered by subcutaneous injection at Weeks 0, 1, 2, 3 and 4 (day 28).
  - ❑ **Maintenance:** 300 mg every 4 weeks (starting on day 56)
- ❑ Pediatric members 12 years and older: Recommended dosage based on body weight and administered by subcutaneous injection at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter

Body Weight at Time of Dosing	Recommended Dose
≥ 30 kg and < 90 kg	150 mg
≥ 90 kg	300 mg

- ❑ Member is ≥ 12 years of age and has a diagnosis of moderate-to-severe **hidradenitis suppurativa**
- ❑ Prescribed by or in consultation with a **Dermatologist**
- ❑ Member tried and failed a 90-day course of oral antibiotics (e.g., tetracycline, minocycline, doxycycline or clindamycin, rifampin) for treatment of HS **(within last 9 months)**

  Name of Antibiotic & Date: _____

Medication being provided by a Specialty Pharmacy – Proprium Rx

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.*

***Approved by Pharmacy and Therapeutics Committee:** ~~7/16/2015; 8/17/2023; 1/18/2024; 11/21/2024; 3/26/2026; 5/28/2026;~~ **9/24/2026**
REVISED/UPDATED/REFORMATTED: ~~8/11/2015; 12/27/2015; 5/6/2016; 8/9/2016; 9/22/2016; 12/11/2016; 8/3/2017; 12/16/2017; 12/31/2018; 9/28/2019; 11/26/2019; 11/18/2020; 11/08/2021; 4/25/2022; 6/15/2022; 6/28/2022; 12/20/2022; 5/26/2023; 8/13/2023; 2/16/2024; 3/26/2024; 4/29/2024; 8/21/2024, 12/17/2024; 7/7/2025, 12/22/2025; 6/15/2026;~~ **8/6/2026**